Lantheus Holdings, Inc.
A maker of radiopharmaceuticals used to image disease, Lantheus' products include PYLARIFY, an F-18 PET agent that lights up prostate cancer on scans, and DEFINITY, a contrast agent for heart ultrasound. The business began in 1956 as New England Nuclear, founded in Boston, and adopted the coined name "Lantheus" in 2008 when it became an independent company — a made-up brand invented to mark its fresh start.
Sold 3.41M
Sold 3.41M
Granted 492.4K · Sold 496.1K
Granted 263.3K · Sold 56.8K
Granted 246.0K · Sold 190.3K
Granted 159.1K · Sold 62.5K
Granted 146.8K · Sold 60.2K
Granted 103.1K · Sold 71.9K
Granted 49.3K · Sold 33.5K
Granted 13.6K · Sold 25.1K
Granted 43.9K
Granted 31.6K · Sold 32.5K
Granted 11.3K · Sold 2.0K
Granted 34.9K
Granted 35.7K
Granted 30.3K
Granted 11.3K · Sold 15.0K
Granted 28.8K · Sold 18.4K
Granted 11.3K · Sold 12.5K
Granted 11.3K · Sold 16.8K
Granted 11.8K · Sold 6
Granted 14.3K
Granted 9.1K
Granted 8.0K
Granted 6.7K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Dapice Joshua J. +9 co-filersMember of a Group Owning 10%, 10% owner, Member of a Group Owning 10% · 2 transactions | — | 10.36Mas of Aug 2025 | — | — | 3.41M |
| Patel Rajiv A +7 co-filersMember of a Group Owning 10% · 2 transactions | — | 10.36Mas of Aug 2025 | — | — | 3.41M |
| Heino Mary AnneExecutive Chair and CEO, Director · 69 transactions | — | 625.7K | 492.4K | — | 496.1K |
| Markison Brian ACEO, Director · 16 transactions | +386.4% | 232.4Kas of Mar 2025 | 263.3K | — | 56.8K |
| Marshall Robert J. Jr.CFO and Treasurer · 39 transactions | -10% | 122.8K | 246.0K | — | 190.3K |
| Niedzwiecki DanielSee Remarks · 36 transactions | +105.9% | 117.5K | 159.1K | — | 62.5K |
| Blanchfield PaulPresident · 37 transactions | +79.4% | 108.2Kas of Aug 2025 | 146.8K | — | 60.2K |
| Montagut EtienneChief Business Officer · 21 transactions | +7.9% | 94.7Kas of Mar 2024 | 103.1K | — | 71.9K |
| Leno Sam RDirector · 21 transactions | +36.4% | 67.2K | 49.3K | — | 33.5K |
| Walker CarolSenior Vice President, Quality · 6 transactions | -14.8% | 64.9Kas of Mar 2022 | 13.6K | — | 25.1K |
| Morgan Amanda MichelleChief Commercial Officer · 8 transactions | — | 64.7K | 43.9K | — | — |
| Sabens AndreaChief Accounting Officer · 42 transactions | -10.2% | 60.4Kas of Jul 2024 | 31.6K | — | 32.5K |
| Thrall James HDirector · 6 transactions | +40.5% | 39.9K | 11.3K | — | 2.0K |
| Provost Jean-ClaudeChief Medical Officer · 3 transactions | — | 38.8Kas of Mar 2024 | 34.9K | — | — |
| Dinkelborg LudgerSee Remarks · 2 transactions | — | 35.7K | 35.7K | — | — |
| Yao Ying VivianChief Human Resources Officer · 2 transactions | — | 30.3Kas of Mar 2022 | 30.3K | — | — |
| McHugh JulieDirector · 8 transactions | -4.7% | 30.1K | 11.3K | — | 15.0K |
| Maeusli Heinz ChristophDirector · 9 transactions | +21.4% | 30.0K | 28.8K | — | 18.4K |
| Pruden Gary JDirector · 8 transactions | — | 29.7K | 11.3K | — | 12.5K |
| Ber GerardDirector · 12 transactions | -13.5% | 27.5K | 11.3K | — | 16.8K |
| Baylor-Henry MinnieDirector · 11 transactions | — | 14.0K | 11.8K | — | 6 |
| Brown KimberlyChief Accounting Officer · 5 transactions | — | 13.9K | 14.3K | — | — |
| Humphrey JeffreyChief Medical Officer · 1 transaction | — | 9.1Kas of Jun 2024 | 9.1K | — | — |
| Eastland Julia MarieDirector · 3 transactions | — | 8.0K | 8.0K | — | — |
| Morrow Phuong KhanhDirector · 2 transactions | — | 7.2K | 6.7K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 5 years: -7.91M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.